INTRODUCTION: Stereotactic body radiation therapy (SBRT) is increasingly being utilized to deliver escalated radiation doses for improving outcomes in various malignancies. We analyzed our cohort of locally advanced, node-positive, and bone oligometastatic prostate cancer patients, that were treated with a combination of pelvic RT using conventional fractionation (CF) and SBRT boost to prostate using extreme hypofractionation (EH), along with hormone therapy (HT). MATERIALS AND METHODS: Outcomes of 44 prospectively treated patients were analyzed. Volumetric modulated arc therapy (VMAT) was utilized to deliver a dose of 45 Gy to pelvic nodal region, 50 Gy to prostate, and 54-56 Gy to gross nodes in 25 fractions. EH boost 18 Gy in three fractions was delivered to the prostate using CyberKnife (Accuray, Sunnyvale, CA, USA) SBRT. Bone oligometastasis, if any, were treated to a dose of 16 Gy in two fractions, delivered on weekends. Serum prostate-specific antigen (PSA), multi-parametric magnetic resonance imaging (MRI) of pelvis, and prostate-specific membrane antigen-positron emission tomography (PSMA-PET) were used for response assessment during follow-up. HT was given as per standard guidelines. RESULTS: There were 33 (75%) locally advanced, nine (20.5%) node-positive, and two (4.5%) oligometastatic cases. At a median follow-up of 63.5 months, the five-year progression-free survival (PFS) was 88.2%, biochemical PFS (bPFS) was 91.4% and overall survival (OS) was 96.9%. Grade III or greater acute genitourinary and gastrointestinal toxicity was 2.3% each, and late toxicity was 4.5% and 0%, respectively. CONCLUSION: Excellent five-year outcomes can be attained even for locally advanced, node-positive and bone oligometastatic prostate cancer, by means of dose-escalation using EH-SBRT boost to the prostate.
INTRODUCTION: Stereotactic body radiation therapy (SBRT) is increasingly being utilized to deliver escalated radiation doses for improving outcomes in various malignancies. We analyzed our cohort of locally advanced, node-positive, and bone oligometastatic prostate cancerpatients, that were treated with a combination of pelvic RT using conventional fractionation (CF) and SBRT boost to prostate using extreme hypofractionation (EH), along with hormone therapy (HT). MATERIALS AND METHODS: Outcomes of 44 prospectively treated patients were analyzed. Volumetric modulated arc therapy (VMAT) was utilized to deliver a dose of 45 Gy to pelvic nodal region, 50 Gy to prostate, and 54-56 Gy to gross nodes in 25 fractions. EH boost 18 Gy in three fractions was delivered to the prostate using CyberKnife (Accuray, Sunnyvale, CA, USA) SBRT. Bone oligometastasis, if any, were treated to a dose of 16 Gy in two fractions, delivered on weekends. Serum prostate-specific antigen (PSA), multi-parametric magnetic resonance imaging (MRI) of pelvis, and prostate-specific membrane antigen-positron emission tomography (PSMA-PET) were used for response assessment during follow-up. HT was given as per standard guidelines. RESULTS: There were 33 (75%) locally advanced, nine (20.5%) node-positive, and two (4.5%) oligometastatic cases. At a median follow-up of 63.5 months, the five-year progression-free survival (PFS) was 88.2%, biochemical PFS (bPFS) was 91.4% and overall survival (OS) was 96.9%. Grade III or greater acute genitourinary and gastrointestinal toxicity was 2.3% each, and late toxicity was 4.5% and 0%, respectively. CONCLUSION: Excellent five-year outcomes can be attained even for locally advanced, node-positive and bone oligometastatic prostate cancer, by means of dose-escalation using EH-SBRT boost to the prostate.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Benedikt Engels; Guy Soete; Koen Tournel; Samuel Bral; Peter De Coninck; Dirk Verellen; Guy Storme Journal: Technol Cancer Res Treat Date: 2009-10
Authors: Mohannad A Awad; Thomas W Gaither; E Charles Osterberg; Gregory P Murphy; Nima Baradaran; Benjamin N Breyer Journal: Prostate Cancer Prostatic Dis Date: 2018-01-02 Impact factor: 5.554
Authors: Nicholas G Zaorsky; Joshua D Palmer; Mark D Hurwitz; Scott W Keith; Adam P Dicker; Robert B Den Journal: Radiother Oncol Date: 2015-05-28 Impact factor: 6.280
Authors: Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-22 Impact factor: 7.038
Authors: Ima Paydar; Abigail Pepin; Robyn A Cyr; Joseph King; Thomas M Yung; Elizabeth G Bullock; Siyuan Lei; Andrew Satinsky; K William Harter; Simeng Suy; Anatoly Dritschilo; John H Lynch; Thomas P Kole; Sean P Collins Journal: Front Oncol Date: 2017-02-07 Impact factor: 6.244
Authors: David Pryor; Mark Sidhom; Sankar Arumugam; Joseph Bucci; Sarah Gallagher; Joanne Smart; Melissa Grand; Peter Greer; Sarah Keats; Lee Wilton; Jarad Martin Journal: Front Oncol Date: 2019-04-02 Impact factor: 6.244
Authors: Catherine Mercado; Marie-Adele Kress; Robyn A Cyr; Leonard N Chen; Thomas M Yung; Elizabeth G Bullock; Siyuan Lei; Brian T Collins; Andrew N Satinsky; K William Harter; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2016-05-06 Impact factor: 6.244
Authors: Pierpaolo Alongi; Riccardo Laudicella; Helena Lanzafame; Andrea Farolfi; Paola Mapelli; Maria Picchio; Irene A Burger; Andrei Iagaru; Fabio Minutoli; Laura Evangelista Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639